Rankings
▼
Calendar
BMRN Q3 2024 Earnings — BioMarin Pharmaceutical Inc. Revenue & Financial Results | Market Cap Arena
BMRN
BioMarin Pharmaceutical Inc.
$12B
Q3 2024 Earnings
Healthcare
Biotechnology
Income Statement
Revenue
$746M
+28.3% YoY
Gross Profit
$557M
74.7% margin
Operating Income
$114M
15.3% margin
Net Income
$106M
14.2% margin
EPS (Diluted)
$0.55
QoQ Revenue Growth
+4.7%
Cash Flow
Operating Cash Flow
$221M
Free Cash Flow
$200M
Stock-Based Comp.
$43M
Balance Sheet
Total Assets
$6.9B
Total Liabilities
$1.4B
Stockholders' Equity
$5.4B
Cash & Equivalents
$675M
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$746M
$581M
+28.3%
Gross Profit
$557M
$453M
+22.9%
Operating Income
$114M
$31M
+273.1%
Net Income
$106M
$40M
+162.7%
Revenue Segments
Product
$734M
98%
Royalty And Other
$12M
2%
← FY 2024
All Quarters
Q4 2024 →